4D Pharma bullish on progress of microbiome-based cancer research

05:43 EDT 21 Mar 2018 | Proactive Investors

4D's lead oncology product has demonstrated immune-stimulatory characteristics in pre-clinical models.

Original Article: 4D Pharma bullish on progress of microbiome-based cancer research

NEXT ARTICLE

More From BioPortfolio on "4D Pharma bullish on progress of microbiome-based cancer research"